Evidence map›Paper›PMID 40368317›Full record

Trial reportContraception2025

Estimating emergency contraception efficacy with levonorgestrel and copper intrauterine devices.

Susan E Nourse, Alexandra L Woodcock, Kathryn S Brown, Alexandra Gero, Lori M Gawron, David K Turok

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Contraception, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Susan E NourseUniversity of Utah School of Medicine, Department of Obstetrics and Gynecology, Salt Lake City, UT, United States. Electronic address: susan.nourse@hsc.utah.edu.
Alexandra L WoodcockUniversity of Utah School of Medicine, Department of Obstetrics and Gynecology, Salt Lake City, UT, United States.
Kathryn S BrownUniversity of Utah School of Medicine, Department of Obstetrics and Gynecology, Salt Lake City, UT, United States.
Alexandra GeroUniversity of Utah School of Medicine, Department of Obstetrics and Gynecology, Salt Lake City, UT, United States.
Lori M GawronUniversity of Utah School of Medicine, Department of Obstetrics and Gynecology, Salt Lake City, UT, United States.
David K TurokUniversity of Utah School of Medicine, Department of Obstetrics and Gynecology, Salt Lake City, UT, United States.

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
RCT Assessing Pregnancy with Intrauterine Devices for Emergency ContraceptionR01HD083340 · NICHD · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI David Turok · 2015 to 2026
$3.6M
NCATS NIH HHS UL1 TR002538NICHD NIH HHS R01 HD083340
6 · The paper itself

Abstract

objectivesThis study aimed to determine observed vs expected pregnancy risk among levonorgestrel 52 mg and copper T380A intrauterine device (IUD) emergency contraception (EC) users. STUDY

designThis is a secondary analysis of participants seeking EC randomly assigned to a levonorgestrel 52 mg or copper T380A IUD. Participants had at least one episode of unprotected intercourse (UPI) in the 5 days preceding enrollment and reported all episodes in the preceding 5 days. We report the proportion of pregnancies prevented of those expected at 1 month following IUD insertion using an established approach that assigns pregnancy risk by menstrual cycle day of intercourse. We calculated proportion of pregnancies prevented using both the day of most recent UPI and all reported UPIs within 5 days of presentation.

resultsOne pregnancy occurred among the 312 participants who received the levonorgestrel 52 mg IUD, with 137 (43.9%) reporting multiple episodes of UPI. No pregnancies occurred among the 318 participants who received the copper IUD, of whom 142 (44.6%) reported multiple episodes. In the levonorgestrel 52 mg IUD group, 14.8 pregnancies were expected using the most recent episode of UPI, and 22.0 pregnancies were expected using all episodes within 5 days of presentation. In the copper IUD group, we calculated 15.0 and 23.1 expected pregnancies, respectively. Levonorgestrel 52 mg IUDs prevented 93.2% to 95.7% of expected pregnancies, and copper IUDs prevented 100% of expected pregnancies.

conclusionsThe results of this analysis provide additional data quantifying the pregnancy risk reduction for both the levonorgestrel 52 mg IUD and copper IUD in a realistic population of EC users. IMPLICATIONS: The levonorgestrel 52 mg IUD for emergency contraception prevented 93% to 96% of expected pregnancies using an established pregnancy risk method, while copper IUD users experienced 100% pregnancy prevention.

Indexed as

Contraception, PostcoitalContraceptive Agents, FemaleIntrauterine Devices, CopperIntrauterine Devices, MedicatedLevonorgestrelAdolescentAdultFemaleHumansPregnancyYoung AdultContraceptive Agents, FemaleLevonorgestrelContraceptionCopperIntrauterine devicesLevonorgestrelMenstrual cyclePostcoital

Identifiers

PMID40368317
PMCPMC13337139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.